company background image
VACC

VaccitechNasdaqGM:VACC Stock Report

Last Price

US$9.61

Market Cap

US$335.2m

7D

-3.3%

1Y

n/a

Updated

27 Jan, 2022

Data

Company Financials +
VACC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VACC Stock Overview

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

Price History & Performance

Summary of all time highs, changes and price drops for Vaccitech
Historical stock prices
Current Share PriceUS$9.61
52 Week HighUS$17.99
52 Week LowUS$7.50
Beta0
1 Month Change-4.09%
3 Month Change-30.31%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-31.84%

Recent News & Updates

Shareholder Returns

VACCUS BiotechsUS Market
7D-3.3%-4.4%-5.1%
1Yn/a-21.2%3.3%

Return vs Industry: Insufficient data to determine how VACC performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how VACC performed against the US Market.

Price Volatility

Is VACC's price volatile compared to industry and market?
VACC volatility
VACC Average Weekly Movement8.6%
Biotechs Industry Average Movement10.4%
Market Average Movement6.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.4%

Stable Share Price: VACC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: VACC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201649Bill Enrighthttps://www.vaccitech.co.uk

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection; VTP-200 for the treatment of human papilloma virus infection; VTP-850 indicated for the treatment of prostate cancer; and VTP-600 for the treatment of non-small cell lung cancer. The company’s prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome.

Vaccitech Fundamentals Summary

How do Vaccitech's earnings and revenue compare to its market cap?
VACC fundamental statistics
Market CapUS$335.19m
Earnings (TTM)-US$46.21m
Revenue (TTM)US$622.26k

538.7x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VACC income statement (TTM)
RevenueUS$622.26k
Cost of RevenueUS$16.06m
Gross Profit-US$15.43m
ExpensesUS$30.77m
Earnings-US$46.21m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.32
Gross Margin-2,480.20%
Net Profit Margin-7,425.72%
Debt/Equity Ratio0%

How did VACC perform over the long term?

See historical performance and comparison

Valuation

Is Vaccitech undervalued compared to its fair value and its price relative to the market?

1.39x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VACC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VACC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VACC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VACC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VACC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VACC is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (2x).


Future Growth

How is Vaccitech forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-20.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VACC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VACC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VACC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VACC's revenue (1.6% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: VACC's revenue (1.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VACC is forecast to be unprofitable in 3 years.


Past Performance

How has Vaccitech performed over the past 5 years?

-150.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: VACC is currently unprofitable.

Growing Profit Margin: VACC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if VACC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare VACC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VACC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: VACC has a negative Return on Equity (-19.16%), as it is currently unprofitable.


Financial Health

How is Vaccitech's financial position?


Financial Position Analysis

Short Term Liabilities: VACC's short term assets ($246.0M) exceed its short term liabilities ($6.4M).

Long Term Liabilities: VACC's short term assets ($246.0M) exceed its long term liabilities ($7.7M).


Debt to Equity History and Analysis

Debt Level: VACC is debt free.

Reducing Debt: VACC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VACC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VACC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 31.1% each year


Dividend

What is Vaccitech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VACC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VACC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VACC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VACC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VACC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Bill Enright (58 yo)

no data

Tenure

US$3,368,628

Compensation

Mr. William J. Enright, also known as Bill, MBA, serves as Chief Executive Officer & Board Director of Vaccitech Limited. He brings a breadth of experiences in a variety of positions within the life scienc...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD3.37M) is above average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: VACC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: VACC only recently listed within the past 12 months.


Top Shareholders

Company Information

Vaccitech plc's employee growth, exchange listings and data sources


Key Information

  • Name: Vaccitech plc
  • Ticker: VACC
  • Exchange: NasdaqGM
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$335.190m
  • Shares outstanding: 34.88m
  • Website: https://www.vaccitech.co.uk

Number of Employees


Location

  • Vaccitech plc
  • The Schrödinger Building
  • Heatley Road
  • Oxford
  • Oxfordshire
  • OX4 4GE
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/27 00:12
End of Day Share Price2022/01/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.